This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vergne, L.
Right arrow Articles by Delaporte, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vergne, L.
Right arrow Articles by Delaporte, E.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2000, p. 3919-3925, Vol. 38, No. 11
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients

Laurence Vergne,1 Martine Peeters,1,* Eitel Mpoudi-Ngole,2 Anke Bourgeois,2 Florian Liegeois,1 Coumba Toure-Kane,3 Souleymane Mboup,3 Claire Mulanga-Kabeya,1 Eric Saman,4 Jacques Jourdan,5 Jacques Reynes,6 and Eric Delaporte1,6

Laboratoire Retrovirus, IRD, Montpellier,1 CHU, Caremeau, 30029 Nimes cedex 4,5 and CHU, Gui de Chauliac, 34295 Montpellier Cedex 5,6 France; Projet PRESICA, BP 906, Yaounde, Cameroon2; CHU, Le Dantec, BP 7325, Dakar, Senegal3; and Innogenetics, 9052 Zwijnaarde, Belgium4

Received 24 February 2000/Returned for modification 11 May 2000/Accepted 17 July 2000

Most human immunodeficiency virus (HIV) drug susceptibility studies have involved subtype B strains. Little information on the impact of viral diversity on natural susceptibility to antiretroviral drugs has been reported. However, the prevalence of non-subtype-B (non-B) HIV type 1 (HIV-1) strains continues to increase in industrialized countries, and antiretroviral treatments have recently become available in certain developing countries where non-B subtypes predominate. We sequenced the protease and reverse transcriptase (RT) genes of 142 HIV-1 isolates from antiretroviral-naive patients: 4 belonged to group O and 138 belonged to group M (9 subtype A, 13 subtype B, 2 subtype C, 5 subtype D, 2 subtype F1, 9 subtype F2, 4 subtype G, 5 subtype J, 2 subtype K, 3 subtype CRF01-AE, 67 subtype CRF02-AG, and 17 unclassified isolates). No major mutations associated with resistance to nucleoside reverse transcriptase inhibitors (NRTIs) or protease inhibitors were detected. Major mutations linked to resistance to non-NRTI agents were detected in all group O isolates (A98G and Y181C) and in one subtype J virus (V108I). In contrast, many accessory mutations were found, especially in the protease gene. Only 5.6% of the 142 strains, all belonging to subtype B or D, had no mutations in the protease gene. Sixty percent had one mutation, 22.5% had two mutations, 9.8% had three mutations, and 2.1% (all group O strains) had four mutations. In order of decreasing frequency, the following mutations were identified in the protease gene: M36I (86.6%), L10I/V (26%), L63P (12.6%), K20M/R (11.2%), V77I (5.6%), A71V (2.8%), L33F (0.7%), and M46I (0.7%). R211K, an accessory mutation associated with NRTI resistance, was also observed in 43.6% of the samples. Phenotypic and clinical studies are now required to determine whether multidrug-resistant viruses emerge more rapidly during antiretroviral therapy when minor resistance-conferring mutations are present before treatment initiation.

* Corresponding author. Mailing address: Laboratoire Retrovirus, IRD, 911 Avenue Agropolis, BP 5045, 34032 Montpellier Cedex 1, France. Phone: 33-4 67 41 62 97. Fax: 33-4 67 61 94 50. E-mail: martine.peeters{at}mpl.ird.fr.

Journal of Clinical Microbiology, November 2000, p. 3919-3925, Vol. 38, No. 11
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Bracciale, L., Colafigli, M., Zazzi, M., Corsi, P., Meraviglia, P., Micheli, V., Maserati, R., Gianotti, N., Penco, G., Setti, M., Di Giambenedetto, S., Butini, L., Vivarelli, A., Trezzi, M., De Luca, A. (2009). Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother 64: 607-615 [Abstract] [Full Text]  
  • Derache, A., Maiga, A.-I., Traore, O., Akonde, A., Cisse, M., Jarrousse, B., Koita, V., Diarra, B., Carcelain, G., Barin, F., Pizzocolo, C., Pizarro, L., Katlama, C., Calvez, V., Marcelin, A.-G. (2008). Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 62: 456-463 [Abstract] [Full Text]  
  • Ndembi, N., Abraha, A., Pilch, H., Ichimura, H., Mbanya, D., Kaptue, L., Salata, R., Arts, E. J. (2008). Molecular Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of Major Drug Resistance Mutations in Newly Diagnosed Patients Infected with Subtypes Other than Subtype B. J. Clin. Microbiol. 46: 177-184 [Abstract] [Full Text]  
  • Baker, C. A. R., Bousheri, S., Ssewanyana, I., Jones, N. G., K'Aluoch, O., Baliruno, D., Ssali, F., Huyen Cao, (2007). HIV Subtypes Distribution and Implication for Antiretroviral Treatment in a Ugandan Population. J Int Assoc Physicians AIDS Care (Chic Ill) 6: 260-263  
  • Jagodzinski, L. L., Cooley, J. D., Weber, M., Michael, N. L. (2003). Performance Characteristics of Human Immunodeficiency Virus Type 1 (HIV-1) Genotyping Systems in Sequence-Based Analysis of Subtypes Other than HIV-1 Subtype B. J. Clin. Microbiol. 41: 998-1003 [Abstract] [Full Text]  
  • Maguire, M. F., Guinea, R., Griffin, P., Macmanus, S., Elston, R. C., Wolfram, J., Richards, N., Hanlon, M. H., Porter, D. J. T., Wrin, T., Parkin, N., Tisdale, M., Furfine, E., Petropoulos, C., Snowden, B. W., Kleim, J.-P. (2002). Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro. J. Virol. 76: 7398-7406 [Abstract] [Full Text]  
  • Fonjungo, P. N., Mpoudi, E. N., Torimiro, J. N., Alemnji, G. A., Eno, L. T., Lyonga, E. J., Nkengasong, J. N., Lal, R. B., Rayfield, M., Kalish, M. L., Folks, T. M., Pieniazek, D. (2002). Human Immunodeficiency Virus Type 1 Group M Protease in Cameroon: Genetic Diversity and Protease Inhibitor Mutational Features. J. Clin. Microbiol. 40: 837-845 [Abstract] [Full Text]  
  • Mracna, M., Becker-Pergola, G., Dileanis, J., Guay, L. A., Cunningham, S., Jackson, J. B., Eshleman, S. H. (2001). Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for Sequence-Based Analysis of Non-Subtype B Human Immunodeficiency Virus Type 1 from Uganda. J. Clin. Microbiol. 39: 4323-4327 [Abstract] [Full Text]  
  • Cane, P. A., de Ruiter, A., Rice, P., Wiselka, M., Fox, R., Pillay, D. (2001). Resistance-Associated Mutations in the Human Immunodeficiency Virus Type 1 Subtype C Protease Gene from Treated and Untreated Patients in the United Kingdom. J. Clin. Microbiol. 39: 2652-2654 [Abstract] [Full Text]  
  • Bao, K., Cohen, S. N. (2001). Terminal proteins essential for the replication of linear plasmids and chromosomes in Streptomyces. Genes Dev. 15: 1518-1527 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»